Thursday, July 7, 2022
Home Business genOway proposes the appointment of Olivier Charmeil (Sanofi) as director

genOway proposes the appointment of Olivier Charmeil (Sanofi) as director

(AOF) – genOway announced the decision of the Board of Directors to propose the appointment of Olivier Charmeil, Executive Vice-President of Sanofi, as a new independent director. This appointment will be submitted to the vote of the General Meeting of Shareholders on June 28, 2022. A graduate of HEC (École des Hautes Etudes Commerciales) and the Institut d’Etudes Politiques (IEP) in Paris, Olivier Charmeil currently oversees the entity General Medicine within the Sanofi group.

“With his experience of nearly 30 years in the field of health, his understanding of the underlying trends in pharmaceutical research and the culture of permanent innovation, Olivier Charmeil comes to support genOway in the pursuit of its strategic repositioning. operated in recent years towards activities with higher profitability “explains the biotechnology company specializing in the design and development of genetically modified research models.

This transformation is materialized today by the development of its range of Catalog models in immuno-oncology which has met with “great commercial success and major innovation projects” aimed at ever better mimicking humans and their disease to help prevent and to heal.

LEAVE A REPLY

Please enter your comment!
Please enter your name here